Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET Fusion-Positive NSCLC By Ogkologos - June 2, 2026 254 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LIBRETTO-432 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Front-line CS1001 Plus Platinum-Based Chemotherapy Delivers Substantial Benefit in Advanced Non-Small... November 21, 2020 EMA Recommends Granting a Marketing Authorisation for Lazertinib December 4, 2024 At 27, She Was Told She Was Too Young For Breast... February 6, 2020 Strengthening EU Support for Rare Cancers under the 2028–2034 Multiannual Financial... November 17, 2025 Load more HOT NEWS Better together: improving brain tumour treatment A Remarkable Group of Patients with Haematological Disorders with No or... Prize winning early detection research Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small...
